Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07169903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT

Study acronym: STAR012
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is a prospective, multicenter randomized controlled trial (RCT) designed to compare the efficacy of segmentectomy and lobectomy for invasive lung adenocarcinoma with a diameter of 2-3 cm and intraoperative frozen section-confirmed IASLC pathological new grade 1-2. The non-inferiority of segmentectomy is primarily evaluated by 5-year relapse-free survival (RFS) and overall survival (OS) after surgery, while secondary endpoints include pulmonary function preservation, perioperative complications, etc. With a planned enrollment of 587 patients over a 3-year recruitment period and a 5-year follow-up, this study aims to identify an optimized surgical approach.
Trial Details
NCT Number NCT07169903
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine, Affiliated Hospital of Nantong University, Huadong Hospital, Anhui Chest Hospital, Ningbo No. 1 Hospital, Ningbo No.2 Hospital, Center hospital of Nanyang, The Affiliated Hospital of Xuzhou Medical University, Huzhou Central Hospital, Anhui Provincial Hospital, Shandong Public Health Clinical Center
Conditions
(from sponsor)		 Lung Adenocarcinoma
Related terms Adenocarcinoma of Lung
Enrollment 587 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov